Archive · 23 Jul 2026
US Announces Phased Tariffs on Generic Drug Imports
The United States has announced a plan to impose tariffs on imported generic drugs starting from August 2026.
For the first two years, there will be no tariffs.
Then, the tariffs will increase to 100% for one year and then to 200% after that.
This plan aims to bring back drug production to the US.
India, which exports a lot of generic drugs to the US, might be affected.
Indian drugs are important for treating many health conditions in the US, like high blood pressure, diabetes, and mental health issues.
The tariffs could make these drugs more expensive for Americans and hurt Indian drug companies.
The US will impose phased tariffs on imported generic drugs starting August 2026.
Initial two years will have 0% tariffs, followed by 100% for one year, and then 200%.
The goal is to reshoring pharmaceutical production to the US.
India, the largest exporter of generic drugs to the US, will be significantly impacted.
Indian drugs make up 38% of US generic drug volume and are crucial for treating various health conditions.
- Who
- US President Donald Trump
- What
- Announcement of phased tariffs on imported generic drugs
- When
- Effective from August 1, 2026
- Where
- United States
- Why
- To reshoring pharmaceutical production and protect US consumers
US Protectionism
Indian Pharmaceutical Industry
Economic Impact
US Protectionism
The US aims to reshoring pharmaceutical production to protect domestic jobs and reduce dependency on imports.
Indian Pharmaceutical Industry
India, as the largest exporter of generic drugs to the US, faces significant economic repercussions and potential job losses.
Healthcare Accessibility
US Protectionism
Higher tariffs may lead to increased domestic production, potentially stabilizing drug prices in the long term.
Indian Pharmaceutical Industry
The tariffs could make generic drugs more expensive for US consumers, affecting accessibility to affordable healthcare.
- Effective Date
- August 1, 2026
- Initial Tariff Period
- 0% for two years
- Second Tariff Period
- 100% for one year
- Subsequent Tariff
- 200% thereafter
- India's Pharma Export to US
- USD 9.7 billion (2024-2025)
- Percentage of US Generic Drugs from India
- 38% by volume
- Key Indian Pharma Companies
- Glenmark Pharmaceuticals Ltd., Lupin Ltd.
Sources
0%, 100%, 200%: Trump's New Generic Drug Tariff Plan May Impact India
Dr Reddy, Aurobindo, Cipla: Pharma Stocks To Remain In Focus Today After Trump's New Generic Drugs Tariff Plan
US to impose steep tariffs on generic medicine imports
Sun Pharma, Zydus Life, Dr Reddy's Labs, Lupin: Pharma shares crash on Trump's fresh levies
US to impose steep tariffs on generic medicine imports
Donald Trump tariff plan puts Indian generic drug exports to US under pressure
